Loading
Everything OnCo dates to 2003: 104 entries, 30 landmarks, 24 papers listed on people's pages, 20 papers and 9 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
104 dated entries in OnCo fall in 2003: 30 landmarks, 24 papers listed on people's pages, 20 papers, 9 approvals, 9 companies founded, 6 journals founded, 3 technologies and 3 trials reported.
Of those, 104 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Advanced symptomatic prostate cancer in men who cannot take GnRH agonists (restricted programme). Withdrawn from the US market in 2005
Prevention of chemotherapy-induced nausea and vomiting (Emend); Ivemend 2008
Prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy (moderately emetogenic added 2005; paediatric suspension 2015)
Relapsed myeloma (accelerated)
Conditioning before haematopoietic progenitor cell transplantation (Busilvex)
NSCLC after chemotherapy (accelerated; restricted 2005)
Moderate to severe Alzheimer's disease (use as a neuroprotectant during whole-brain radiotherapy is off-label)
Acute and delayed nausea and vomiting with moderately emetogenic chemotherapy; acute with highly emetogenic chemotherapy (paediatric from 1 month added 2014)
Acromegaly with inadequate response to surgery or radiotherapy and other medical therapies
The year reported on trial records, with the headline result the record gives.
5-year EFS 69% vs 54% (localised).
Median survival 22.3 against 12.6 months (p=0.032), with 8 percent treatment-related mortality.
Larynx preservation at 2 years 88% (concurrent) vs 75% (induction) vs 70% (radiotherapy alone).
The publication year on key paper records.
Prados MD, Schold SC, Fine HA, et al. Neuro-Oncology.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Proceedings of the National Academy of Sciences.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. New England Journal of Medicine.
Swain SM, Whaley FS, Ewer MS. Cancer.
Doronina SO, Toki BE, Torgov MY, et al. Nature Biotechnology.
Foulkes WD, Stefansson IM, Chappuis PO, et al. Journal of the National Cancer Institute.
O'Brien SG, Guilhot F, Larson RA, et al. New England Journal of Medicine.
Heinrich MC, Corless CL, Demetri GD, et al. Journal of Clinical Oncology.
Heinrich MC, Corless CL, Duensing A, et al. Science.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Journal of Clinical Oncology.
Verwaal VJ, van Ruth S, de Bree E, et al. Journal of Clinical Oncology.
Citron ML, Berry DA, Cirrincione C, et al. Journal of Clinical Oncology.
Sørlie T, Tibshirani R, Parker J, et al. Proceedings of the National Academy of Sciences.
Forastiere AA, Goepfert H, Maor M, et al. New England Journal of Medicine.
Shattuck TM, Välimäki S, Obara T, et al. New England Journal of Medicine.
Grossman HB, Natale RB, Tangen CM, et al. New England Journal of Medicine.
Fidler IJ. Nature Reviews Cancer.
Tonon G, Modi S, Wu L, et al. Nature Genetics.
Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. The American journal of medicine.
Bergers G, Benjamin LE. Nature Reviews Cancer.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Multiple myeloma
Relapsed or refractory multiple myeloma
Newly diagnosed multiple myeloma, transplant-eligible
Multiple myeloma
Thyroid cancer
Papillary thyroid cancer
HER2-positive breast cancer with brain metastases
Triple-negative breast cancer (TNBC). Sørlie's independent data sets and Foulkes's cytokeratin 5/6 stain (odds ratio 9.0) linked hereditary and basal-like disease; Atchley (2008) f...
NUT carcinoma (midline carcinoma with NUTM1 rearrangement). French and colleagues identify the fusion gene.
Mucoepidermoid carcinoma
Salivary gland cancers
Colorectal cancer. Verwaal, 105 patients: median survival 22.3 versus 12.6 months, at 8 percent treatment-related mortality.
Mesothelioma
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Cancer of unknown primary (CUP)
Primary mediastinal (thymic) large B-cell lymphoma
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
PDGFRA D842V-mutant GIST
Ewing sarcoma
Sarcomas (soft tissue, bone, GIST)
Chronic myeloid leukaemia, chronic phase
Muscle-invasive and advanced bladder cancer
Gastrointestinal stromal tumour (GIST)
Pleural mesothelioma
Laryngeal and hypopharyngeal cancer
Hypopharyngeal cancer
Mucinous ovarian cancer
Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)
Parathyroid carcinoma. Shattuck and colleagues, NEJM.
Bladder & urothelial cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Amsterdam / Irvine, CA
La Jolla, California
Nanjing
Hangzhou
Villejuif
Irvine, CA / Herstal
Paris, France
Tokyo
Ann Arbor, Michigan
The founded year on journal records.
Wiley
Millennium Medical Publishing
Springer
Harborside
Wiley
BMC (Springer Nature)
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Science
Nature Medicine
Blood
Journal of Clinical Oncology
J Biol
NEJM
NEJM
Nature
Nature
Current Opinion in Immunology
Nature
International Journal of Radiation Oncology*Biology*Physics
Revista do Colégio Brasileiro de Cirurgiões
Modern Pathology
Annals of Medicine
Br J Cancer
Journal of Clinical Oncology
JCO
Blood Reviews
PNAS
New England Journal of Medicine
Journal of Pediatric Surgery
Nature Reviews Cancer
Journal of Clinical Oncology